tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Tharimmune Stockholders Approve Key Strategic Proposals

Story Highlights
  • Tharimmune stockholders approved increasing shares reserved under the equity plan to 2,000,000.
  • Stockholders authorized potential increase of total shares to up to 1,000,000,000 and non-public offerings.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Tharimmune Stockholders Approve Key Strategic Proposals

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest announcement is out from Tharimmune ( (THAR) ).

On October 9, 2025, Tharimmune, Inc. held a special meeting where stockholders approved several key proposals. These included an amendment to increase the number of shares of common stock reserved under the 2023 Omnibus Equity Incentive Plan to 2,000,000 shares, an authorization for the board to potentially increase the total authorized shares of common stock to up to 1,000,000,000, and permission to issue securities in non-public offerings. These decisions reflect strategic moves to enhance Tharimmune’s operational flexibility and potential market positioning.

The most recent analyst rating on (THAR) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Tharimmune stock, see the THAR Stock Forecast page.

More about Tharimmune

Average Trading Volume: 10,000,443

Technical Sentiment Signal: Hold

Current Market Cap: $16.63M

For a thorough assessment of THAR stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1